Loading
Instead of attacking the cancer cell, engineering T cells to strip away the scaffolding and the suppressive immune cells that protect it.
FAP-directed CAR-T depletes cancer-associated fibroblasts and, in mouse models, opens desmoplastic tumours to chemotherapy and immunity; a small Swiss study delivered FAP CAR-T into the pleural cavity in mesothelioma. Myeloid-directed approaches target CSF1R, TREM2, or CD163 populations. The recurring problem is that FAP and myeloid markers are not tumour-specific: FAP is expressed in bone-marrow stroma and healing tissue, and murine FAP CAR-T caused cachexia and marrow toxicity in early studies.
A CAR recognises a stromal antigen rather than a tumour antigen; killing the supporting cells collapses the niche the tumour depends on.
Query for this technology: (TITLE:"CAR-T against stroma: fibroblasts and myeloid cells" OR ABSTRACT:"CAR-T against stroma: fibroblasts and myeloid cells") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CAR-T against stroma: fibroblasts and myeloid cells, not a curated reading list.
Shares Radical oncology: what could change the war by 2035, Pancreatic ductal adenocarcinoma and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035, Pancreatic ductal adenocarcinoma and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.
Shares Radical oncology: what could change the war by 2035 and the tags frontier, radical.